Information Provided By:
Fly News Breaks for June 27, 2017
VSAR
Jun 27, 2017 | 05:29 EDT
Piper Jaffray analyst Edward Tenthoff says he's a buyer of Versartis shares ahead of the Phase III Velocity data on somavartan in pediatric growth hormone deficiency expected in September. The analyst is "confident" somavaratan will meet the primary endpoint of non-inferior height velocity at 12 months based on Phase II Vista data that showed consistent HV out to three years. He reiterates an Overweight rating on the shares with a $26 price target.
News For VSAR From the Last 2 Days
There are no results for your query VSAR